Comparison of the Effects of Weight Changes on Serum Adipokines in Patients Diagnosed With Anorexia Nervosa and Morbid Obesity

Not Applicable

Completed

• Conditions: Anorexia Nervosa; Bariatric Surgery; Weight Change, Body
• Interventions: Behavioral: Dietary intervention; Procedure: Bariatric surgery-RYGB

• Registration Number: NCT04663919
• Lead Sponsor: Istanbul University

Brief Summary

In this study, when patients diagnosed with AN started treatment and their weight increased by 10%; On the other hand, it was aimed to compare the changes in serum adipokine levels observed in morbidly obese patients before bariatric surgery and when they lost 10% of their post-op weight with both anthropometric measurements, biochemical parameters, and values of healthy volunteers.

Detailed Description

The most characteristic feature of obesity is the increase in adipose tissue. On the contrary, in anorexia nervosa, there is a decrease in adipose tissue enough to impair neuroendocrine functions. Adipose tissue is formed by loosely binding lipid-filled cells called adipocytes and is now considered an important part of energy metabolism. Adipokines it secretes play a role in many physiological processes of the body such as nutrition, appetite, energy balance, insulin, and glucose metabolism, lipid metabolism, regulation of blood pressure, vascular remodeling, coagulation, and inflammation.

Therefore, changes in the amount of body fat in these two patient groups, which are at the two ends of the spectrum, affect both the biochemical parameters and physiological functions of the patients in different ways. It is expected that both adipokine levels and biochemical parameters will approach the values of healthy subjects with a decrease in adipose tissue of clinically morbidly obese patients and an increase in adipose tissue of patients with AN. However, in some studies comparing the parameters of patients with constitutionally weak patients and patients with AN, results contrary to expectations were obtained. In this study, we compared the extent to which weight changes changed adipokines and correlated with biochemical parameters based on healthy and normal-weight volunteers.

Study Timeline

• Study Start: 2014-01-01
• Primary Completion: 2014-04-07
• Study Completion: 2015-01-01
• Status Verified: 2020-12
• Study First Submitted: 2020-12-05
• Study First Submitted QC: 2020-12-10
• Study First Posted: 2020-12-11
• Last Update Submitted: 2020-12-14
• Last Update Posted: 2020-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• for Anorexia Nervosa group:

  • Have been diagnosed with anorexia nervosa
  • BMI <18 kg/m2
  • Good general health
  • Volunteering to participate in the study

• for Morbidly Obese group:

  • Who was diagnosed with morbid obesity and planned to undergo RYGB operation
  • BMI> 40 kg/m2
  • Volunteering to participate in the study

• for Healthy Volunteers:

  • Good general health
  • BMI >20 and <30 kg/m2
  • Volunteering to participate in the study

Exclusion Criteria

• <13 and> 60 years old
• to had type 2 diabetes, hypertension, liver and kidney failure, cancer, or a chronic disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anorexia Nervosa	Dietary intervention	Patients diagnosed with Anorexia Nervosa, having a BMI of \<18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
Morbidly Obese	Bariatric surgery-RYGB	Patients with a BMI\> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)

Primary Outcome Measures

Name	Time	Method
Plasma Leptin levels changes:	3 months on average	Change in baseline Leptin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples.
Plasma Apelin levels changes	3 months on average	Change in baseline Apelin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples.
Plasma Omentin levels changes	3 months on average	Change in baseline Omentin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples.
Plasma Adiponectin levels changes	3 months on average	Change in baseline Adiponectin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples.
Plasma IL-6 levels changes	3 months on average	Change in baseline IL-6 levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples.

Secondary Outcome Measures

Name	Time	Method
Weight change	3 months on average	Change in baseline weight (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight.
Fat mass change	3 months on average	Change in baseline fat mass (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight.
Fat free mass changes	3 months on average	Change in baseline fat free mass (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight.